Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAT-05
- Development stage
- Preclinical
- Lead developer
- DRC
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HAT-05 is a topical pharmaceutical cream currently under development by the Japanese company **DRC** (Drug Research Center Co., Ltd.) for the treatment of **atopic dermatitis**. The drug is part of DRC's in-house pipeline and is categorized under allergic conditions. As of the latest pipeline updates, HAT-05 is in the **preclinical to early clinical** development stage in Japan. While specific details regarding its molecular target or mechanism of action have not been publicly disclosed, it is formulated as a cream intended for localized application to manage skin inflammation and symptoms associated with atopic dermatitis.
Beyond the preview
Go deeper on HAT-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAT-05.